Frequency Therapeutics, Inc

FREQ NASDAQ
FREQ
Frequency Therapeutics, Inc NASDAQ
 
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E

FREQ Stock Chart

Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Health Technology
Industry: Biotechnology
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The firm's progenitor cell activation approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. Its product pipeline include Sensorineural hearing loss (FX-322), and Multiple Sclerosis. The company was founded by Robert S. Langer, Jr., David L. Lucchino, Christopher Loose and Will J. McLean on November 13, 2014 and is headquartered in Woburn, MA.

Breaking news